Clinical use and monitoring of adverse effects of sodium‐glucose cotransporter‐2 inhibitors in persons with type 1 diabetes mellitus

Documenti analoghi

• Effect of sodium–glucose cotransporter 2 inhibitors on serum low‐density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus
  di: Tasuku Imada, et al.
  Pubblicazione: (2024)
• The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression
  di: Yen‐Chen Chiu, et al.
  Pubblicazione: (2025)
• Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study (RESTORE‐nephropathy study)
  di: Ayako Shigeta, et al.
  Pubblicazione: (2025)
• Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
  di: Kyoung Hwa Ha, et al.
  Pubblicazione: (2024)
• Comment on “The impact of dynamic kidney function prior to using sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes patients with low‐risk renal disease progression”
  di: Shyam Sundar Sah, et al.
  Pubblicazione: (2025)